Abstract

OUTCOME OF PATIENTS WITH CHRONIC HEPATITIS C INFECTION, TREATED BY DACLATASVIR AND SOFOSBUVIR AT MILITARY HOSPITAL, SANA’A, YEMEN

Dr. Akram Yahya Alhaj*, Ahmed Kaid Salem, Yahya Alazy, Ashjan Hassan Alwazeer and Amin Abdulrab

Abstract

Background: The prevalence of Hepatitis C virus (HCV) has been reported to be low in developed countries, although it remains a major public health concern in different Meddle East countries including Yemen. Aim of the Study: To determine efficacy and tolerance of the new drugs Daclatasvir + Sofosbuvir on patients with hepatitis C virus infection Presented into the Military Hospital, Sana’a, Yemen. Study design: This was a prospective descriptive study conducted at Hepatology Center in the Military Hospital, Sana’a, Yemen, over 13 months from July 2017 to August 2018. It was involved all patients diagnosed with chronic hepatitis C infection. Patients were received combined therapy Sofosbuvir/Daclatasvir with or without ribavirin for 12 weeks as scheduled. Baseline parameters were recording and follow up for the full duration of the study, Sustained Virological response (SVR12) adverse effect were recorded. Results: A total number of the patients presented with hepatitis were 652. Of these Seventy patients were full field the inclusion criteria an enrolled in this study. 41.4% were males and 58.5% were females the mean age was 47±6.1 years. Hepatitis C Genotype[1] was the most common type (48.5%) followed by genotype[4] (44.2%). Sofosbuvir/Daclatasvir were given to 62 patients and ribavirin was added to 8 patients. The Sustained Virological response (SVR12) was 98.5%. The adverse drug reactions were fatigue (31.4%) gastritis 5.7%, loss of appetite 4.2% and headache (30%). Conclusion: Treatment of chronic hepatitis C infection with combination of Sofosbuvir/Daclatasvir ± Ribavirin is very effective in eradication the disease. These drugs showed a good safety profile and did not show any serious complications.

Keywords: Hepatitis C Virus, Sofosbuvir, Daclatasvir, Yemen.